Personalis, Inc. (NASDAQ: PSNL – Get a rating) CFO Aaron Tachibana sold 4,187 shares in a trade that took place on Thursday, June 2. The stock was sold at an average price of $3.59, for a total value of $15,031.33. Following the transaction, the CFO now owns 242,201 shares of the company, valued at $869,501.59. The transaction was disclosed in a document filed with the SEC, accessible via this link.
Aaron Tachibana also recently made the following trade(s):
- On Monday, May 16, Aaron Tachibana sold 1,286 shares of Personalis. The stock was sold at an average price of $4.86, for a total trade of $6,249.96.
Shares of Personalis were down $0.32 on Monday, hitting $3.50. The company had a trading volume of 946,179 shares, compared to its average volume of 496,410. Personalis, Inc. has a 1-year low of $3.47 and a 1-year high of $28.47. The stock has a 50-day moving average of $5.87 and a 200-day moving average of $9.64. The stock has a market capitalization of $159.06 million, a price-earnings ratio of -1.92 and a beta of 1.74.
Personalis (NASDAQ:PSNL- Get a rating) last released its quarterly results on Wednesday, May 4. The company reported ($0.63) EPS for the quarter, missing analyst consensus estimates of ($0.57) by ($0.06). Personalis had a negative net margin of 101.49% and a negative return on equity of 25.70%. In the same period of the previous year, the company had earned earnings per share of ($0.29). As a group, analysts expect Personalis, Inc. to post -2.52 EPS for the current year.
Several equity analysts have recently weighed in on PSNL shares. Zacks Investment Research upgraded shares of Personalis from a “sell” rating to a “hold” rating in a Saturday, April 23 report. Citigroup lowered its price target on Personalis from $18.00 to $14.00 in a Thursday, May 5 research note. Oppenheimer reduced his price target on Personalis from $30.00 to $24.00 and set an “outperform” rating for the company in a Friday, Feb. 25 research note. Finally, HC Wainwright lowered its target price on Personalis from $38.00 to $30.00 in a Thursday, May 5 research report. Three analysts rated the stock with a hold rating and five gave the company a buy rating. According to MarketBeat.com, Personalis currently has an average rating of “Buy” and a consensus target price of $24.86.
Several hedge funds have recently changed their positions in PSNL. ARK Investment Management LLC increased its position in Personalis shares by 6.1% during the first quarter. ARK Investment Management LLC now owns 5,184,784 shares of the company valued at $42,463,000 after purchasing an additional 296,669 shares last quarter. BlackRock Inc. increased its stake in Personalis shares by 3.4% in the 1st quarter. BlackRock Inc. now owns 4,538,555 shares of the company worth $37,171,000 after purchasing an additional 149,222 shares in the last quarter. Millennium Management LLC increased its position in Personalis shares by 533.6% during the fourth quarter. Millennium Management LLC now owns 1,350,852 shares of the company valued at $19,277,000 after acquiring an additional 1,137,636 shares in the last quarter. Alyeska Investment Group LP increased its position in shares of Personalis by 26.8% during the first quarter. Alyeska Investment Group LP now owns 957,676 shares of the company valued at $7,843,000 after acquiring an additional 202,592 shares in the last quarter. Finally, Wellington Shields Capital Management LLC increased its position in Personalis by 1.3% in the fourth quarter. Wellington Shields Capital Management LLC now owns 922,990 shares of the company worth $13,171,000 after purchasing an additional 12,204 shares in the last quarter. Institutional investors hold 86.47% of the company’s shares.
Personalis company profile (Get a rating)
Personalis, Inc operates as a worldwide cancer genomics company. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for the tumor and its immune microenvironment, from a single limited sample of tissue or plasma; ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offer for personalized tumor monitoring for patients; NeXT Dx Test, a cancer genomic profiling test enabling composite biomarkers for cancer therapy; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Personalis right now?
Before you consider Personalis, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off… and Personalis wasn’t on the list.
Although Personalis currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here